Trial
NCT01278745
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Clinical Trials in Organ Transplantation; Genentech, Inc.; Rho Federal Systems Division, Inc.
Condition
Cardiac Allograft Vasculopathy
Intervention
Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Why stopped
Due to inability to meet accrual goals within the funding period
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-25